MiQuit 3 trial
Research type
Research Study
Full title
RCT and meta-analysis testing effectiveness and cost-effectiveness of a tailored text message programme (MiQuit) for smoking cessation in pregnancy
IRAS ID
230578
Contact name
Angela Shone
Contact email
Sponsor organisation
University of Nottingham
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 2 months, 1 days
Research summary
In high income countries 13% - 25% of pregnant women smoke and rates are increasing in developing countries.
Pregnancy is the life event which most motivates cessation attempts. Self-help support (SHS) almost doubles likelihood of cessation in late pregnancy. However, SHS programmes which help pregnant smokers to quit were all developed before easily-accessible technologies became widely available.
MiQuit is a text-message, smoking cessation SHS programme for pregnant smokers previously developed to address the lack of acceptable SHS for pregnant smokers. MiQuit advice is relevant to pregnancy as it is highly-tailored to gestation.
The trial aims to determine whether or not MiQuit is effective when offered in addition to standard behavioural support for smoking cessation in pregnancy. The efficacy of the MiQuit system will be assessed by combining the findings from this trial with the findings from the previous two MiQuit trials.
Women who are less than 25 weeks gestation in their pregnancy and who smoke either at least 5 cigarettes per day pre-pregnancy and/or smoking at least 1 cigarette on a typical day during pregnancy will be eligible to take part in the study. Women will be identified as they attend hospitals antenatal screening (ultrasound) appointments or from medical records.
If consented participants will be randomised to either control (NHS smoking cessation support which they choose to access + standard NHS stop smoking leaflet) or intervention (all control group interventions + MiQuit text message cessation programme). Participants will be followed up at 4 weeks after randomisation for a short questionnaire, and then at 36 weeks gestation for a longer questionnaire. For those participants who report quitting smoking we will request a saliva and carbon monoxide reading.
The total duration of the study is 36 months. The maximum possible duration of a participant’s involvement in the trial is approximately 40 weeks.REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
17/EM/0327
Date of REC Opinion
10 Oct 2017
REC opinion
Further Information Favourable Opinion